Enovis Corporation $ENOV Stake Reduced by Universal Beteiligungs und Servicegesellschaft mbH

Universal Beteiligungs und Servicegesellschaft mbH trimmed its stake in Enovis Corporation (NYSE:ENOV) by 99.0% during the third quarter, HoldingsChannel.com reports. The institutional investor owned 8,552 shares of the company’s stock after selling 888,425 shares during the quarter. Universal Beteiligungs und Servicegesellschaft mbH’s holdings in Enovis were worth $259,000 as of its most recent filing with the SEC.

Several other institutional investors have also modified their holdings of the company. Farther Finance Advisors LLC increased its holdings in shares of Enovis by 42.8% in the 3rd quarter. Farther Finance Advisors LLC now owns 1,224 shares of the company’s stock worth $37,000 after acquiring an additional 367 shares during the period. EverSource Wealth Advisors LLC grew its holdings in Enovis by 125.4% in the 2nd quarter. EverSource Wealth Advisors LLC now owns 1,271 shares of the company’s stock worth $40,000 after buying an additional 707 shares in the last quarter. Elevation Point Wealth Partners LLC bought a new position in Enovis in the 2nd quarter worth approximately $46,000. SJS Investment Consulting Inc. increased its position in Enovis by 30,340.0% in the 3rd quarter. SJS Investment Consulting Inc. now owns 1,522 shares of the company’s stock valued at $46,000 after acquiring an additional 1,517 shares during the period. Finally, Nisa Investment Advisors LLC raised its stake in Enovis by 235.2% during the 3rd quarter. Nisa Investment Advisors LLC now owns 1,703 shares of the company’s stock valued at $52,000 after acquiring an additional 1,195 shares in the last quarter. Institutional investors own 98.45% of the company’s stock.

Analysts Set New Price Targets

Several research analysts have recently issued reports on ENOV shares. Weiss Ratings reissued a “sell (d-)” rating on shares of Enovis in a research note on Wednesday, October 8th. UBS Group reiterated a “buy” rating and issued a $50.00 price objective on shares of Enovis in a report on Monday, January 5th. Wells Fargo & Company boosted their target price on Enovis from $41.00 to $42.00 and gave the stock an “overweight” rating in a report on Friday, November 7th. BTIG Research assumed coverage on Enovis in a research note on Tuesday, January 6th. They set a “buy” rating and a $41.00 price target for the company. Finally, Evercore ISI reissued an “outperform” rating on shares of Enovis in a research note on Monday, January 12th. Seven research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $46.71.

Enovis Trading Down 1.8%

Shares of NYSE:ENOV opened at $21.78 on Wednesday. The company has a debt-to-equity ratio of 0.66, a quick ratio of 1.16 and a current ratio of 2.22. The stock has a market capitalization of $1.25 billion, a price-to-earnings ratio of -0.92 and a beta of 1.52. Enovis Corporation has a 1-year low of $21.00 and a 1-year high of $47.26. The company has a 50 day moving average price of $26.20 and a 200 day moving average price of $28.77.

Enovis (NYSE:ENOV) last announced its quarterly earnings data on Thursday, November 6th. The company reported $0.75 EPS for the quarter, beating analysts’ consensus estimates of $0.67 by $0.08. The company had revenue of $548.91 million during the quarter, compared to the consensus estimate of $538.61 million. Enovis had a positive return on equity of 7.79% and a negative net margin of 61.22%.The company’s quarterly revenue was up 8.7% compared to the same quarter last year. During the same quarter in the prior year, the firm earned $0.73 EPS. Enovis has set its FY 2025 guidance at 3.100-3.250 EPS. On average, research analysts anticipate that Enovis Corporation will post 2.79 EPS for the current fiscal year.

Insider Transactions at Enovis

In related news, EVP Daniel A. Pryor sold 999 shares of the company’s stock in a transaction that occurred on Tuesday, December 9th. The shares were sold at an average price of $27.20, for a total value of $27,172.80. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, insider John Kleckner acquired 2,468 shares of the firm’s stock in a transaction that occurred on Tuesday, November 25th. The stock was purchased at an average cost of $30.32 per share, with a total value of $74,829.76. Following the purchase, the insider directly owned 12,302 shares in the company, valued at approximately $372,996.64. This trade represents a 25.10% increase in their position. The disclosure for this purchase is available in the SEC filing. Company insiders own 2.70% of the company’s stock.

Enovis Company Profile

Enovis is a global medical technology company focused on advancing the field of musculoskeletal health. Formed through the separation of the MedTech business from Colfax Corporation in 2021, Enovis brings together a portfolio of specialized products and services designed to address conditions affecting the foot and ankle, hand and wrist, sports medicine, joint repair, biologics and rehabilitation.

The company’s flagship offerings include minimally invasive implants and instrumentation for foot and ankle surgery under the Treace Medical Concepts brand, focal joint resurfacing implants through Arthrosurface, and synthetic bone graft substitutes marketed as NovaBone.